BETA


2012/0035(COD) Medicinal products for human use: transparency of measures regulating the prices and their inclusion in the scope of public health insurance systems

Progress: Procedure lapsed or withdrawn

RoleCommitteeRapporteurShadows
Lead ENVI PARVANOVA Antonyia (icon: ALDE ALDE) MAZEJ KUKOVIČ Zofija (icon: EPP EPP), CHILDERS Nessa (icon: S&D S&D), RIVASI Michèle (icon: Verts/ALE Verts/ALE), CABRNOCH Milan (icon: ECR ECR), SOUSA Alda (icon: GUE/NGL GUE/NGL), CYMAŃSKI Tadeusz (icon: EFD EFD)
Former Responsible Committee ENVI
Former Responsible Committee ENVI FARIA José Inácio (icon: ALDE ALDE)
Committee Opinion EMPL
Committee Opinion ITRE
Committee Opinion IMCO BUŞOI Cristian-Silviu (icon: ALDE ALDE)
Committee Opinion JURI
Former Committee Opinion EMPL
Former Committee Opinion EMPL
Former Committee Opinion ITRE
Former Committee Opinion ITRE
Former Committee Opinion IMCO
Former Committee Opinion IMCO Ashley FOX (icon: ECR ECR), Matteo SALVINI (icon: ENF ENF)
Former Committee Opinion JURI
Former Committee Opinion JURI
Lead committee dossier:
Legal Basis:
TFEU 114-p1

Events

2015/03/07
   EC - Proposal withdrawn by Commission
2014/10/23
   EP - Former Responsible Committee
2013/05/30
   EDPS - Document attached to the procedure
Details

Opinion of the European Data Protection Supervisor on the amended Commission proposal for a directive on the transparency of measures regulating the prices of

medicinal products for human use and their inclusion in the scope of public health insurance systems.

The opinion focuses on the following aspects of the proposed directive relating to personal data protection:

Applicability of the data protection legislation: a reference should provide as a general rule that Directive 95/46/EC and Regulation (EC) No 45/2001 apply to the processing of personal data within the framework of the proposed directive;

Publication of data concerning experts and members of certain organisations: subject to the outcome of a proportionality test, the publication obligation should in any event be supported by adequate safeguards to ensure respect of the rights of the persons concerned to object, the security/accuracy of the data and their deletion after an adequate period of time;:

Potential processing of data concerning the health of patients due to access to data regarding market authorisation data: new provisions should be introduced in order to:

· clearly define in which situations and subject to what safeguards information containing patient health data will be processed, as well as safeguards in this regard;

· provide for a requirement to fully anonymise any patient data included in the market authorisation data before this data is transferred to the competent authority for any further processing for purposes of pricing and reimbursement decisions.

Creation of databases at EU.Member State levels: a data protection impact assessment should be carried out in advance, before any further action is undertaken with a view to launching any new database.

2013/05/22
   ESC - Economic and Social Committee: opinion, report
Documents
2013/05/15
   PT_PARLIAMENT - Contribution
Documents
2013/04/04
   Commission response to text adopted in plenary
Documents
2013/03/21
   EP/CSL - Formal reconsultation of Parliament
2013/03/18
   EC - Amended legislative proposal for reconsultation published
Details

The Commission presents an amended proposal for the Directive on the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems. The European Parliament will be consulted again on this proposal.

Background: the Commission presented its initial legislative proposal on 1st March 2012 ( please refer to the summary of the same date ). Negotiations in the Council Working Party on Pharmaceuticals and Medical Devices proved to be difficult. The main concerns of Member States were related to: (i) the principle of subsidiarity; (ii) the remedies procedure; (iii) the creation of a system of pre-notification of draft national measures to the Commission; (iv) the shortening of the time limits for taking decisions on pricing of medicines and their inclusion in the scope of health insurance systems; (v) the distinction between originator medicinal products subject to health technology assessment (HTA) and those not subject to HTA; (vi) the obligation to consult the interested parties.

As the result of the European Parliament’s position in 1st reading on 6 February 2013 ( please refer to the summary of that date ) and taking into consideration the position of Member States in the Council, the Commission decided to amend its proposal.

It took into account the amendments of the European Parliament voted in plenary : 50 were acceptable (16 as such and 34 acceptable in principle, even if, a few of them were acceptable only in part) and only 7 were unacceptable.

The main amendments to the initial proposal are as follows:

Minimum procedural requirements : these should ensure legal certainty and transparency for all the parties involved in the process of pricing of medicinal products and inclusion in the health insurance systems, while promoting the production of medicinal products, accelerating the entry into the market of generic medicinal products and encouraging research and development of new medicinal products.

Definitions : the amended proposal inserted a definition for “biosimilar medicinal product” which means a biological medicinal product that is similar to a reference biological medicinal product.

The concept of “ health technology assessment ” is clarified: it means an assessment which as a minimum includes the assessment of the relative efficacy or of the short- and long-term effectiveness of the medicinal product compared to other health technologies or interventions in use for treating the associated condition.

Price approval : a decision on the price which may be charged for the medicinal product concerned is adopted and communicated to the applicant within 90 days (rather than 60 days as stated in the initial proposal) of the receipt of an application submitted. With respect to generic medicinal products, that time limit shall be 30 days (15 days in the initial proposal), provided that the price of the reference medicinal product has been approved by the competent authorities.

Where Member States decide to include health technology assessment as part of their decision-making process on the pricing of medicinal products, such assessment shall be carried out within these time limits.

Price increase: a decision to approve or reject on an application to increase the price of a medicinal product must be adopted and communicated to the applicant within 90 days of its receipt.

Price freeze and price reduction: once a year Member States shall assess whether the price freeze or the price reduction is still justified taking into account the macro-economic conditions and adopt necessary changes where appropriate.

Inclusion of medicinal products in health insurance systems: the amended proposal states that a decision must be adopted and communicated to the applicant within 90 days of its receipt. With respect to generic medicinal products, that time limit shall be 30 days , provided that the reference medicinal product has already been included in the public health insurance system.

Irrespective of the organisation of their internal procedures, Member States shall ensure that the overall period of time taken by the inclusion procedure and the price approval procedure does not exceed 180 days . With respect to generic medicinal products, that time limit shall not exceed 60 days, provided that the reference medicinal product has already been included in the public health insurance system.

Furthermore, information on information on the criteria which the competent authorities must take into account when deciding whether or not to include medicinal products within the scope of the public health insurance system must be made public, as must information regarding decision-making bodies at national or regional level.

Additional proof of quality, safety, efficacy or bioequivalence : in the framework of pricing and reimbursement decisions, Member States shall not re-assess the elements on which the marketing authorisation is based, including the quality, safety, efficacy, or bioequivalence, or biosimilarity of the medicinal product or the criteria for orphan designation which have already been assessed during the marketing authorisation procedure.

Consultation of interested parties: where a Member State intends to adopt or amend any legislative measure falling within the scope of the Directive, it shall give civil society organisations, including patient and consumer groups, and other interested parties, the opportunity to comment on the draft measure within a reasonable period.

2013/02/06
   EP - Results of vote in Parliament
2013/02/06
   EP - Decision by Parliament, 1st reading/single reading
Details

The European Parliament adopted by 559 votes to 54, with 72 abstentions, a legislative resolution on the proposal for a Directive of the European Parliament and of the Council relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems .

Parliament adopted its position at first reading under the ordinary legislative procedure. Its amendments are as follows:

Scope: this Directive may not call into question a marketing authorisation relating to a medicinal product granted in accordance with the procedure referred to in Directive 2001/83/EC .

Definitions: Parliament defines a “ voluntary contractual agreement ” as an agreement concluded between public authorities and the marketing authorisation holder for a medicinal product which is neither mandatory nor required by law, nor the only alternative to being included in the national pricing and reimbursement scheme to ensure that agreements are not used as a loophole to avoid the applicability of the Directive. A “ biosimilar medicinal product ” means a similar biological medicinal product approved in accordance with Directive 2001/83/EC. “ Health technology assessment ” (HTA) means an assessment which as a minimum includes the relative efficacy or the short- and long-term effectiveness of the medicinal product compared to other health technologies or interventions in use for treating the associated condition.

Criteria underlying decisions regulating prices of medicinal products: Parliament introduces a new recital requiring that the criteria underlying any decision directly or indirectly regulating the prices of medicinal products, as well as any measure determining the extent to which they shall be covered by public health insurance systems, include the assessment of unmet medical needs, clinical and societal benefits and innovation . Such criteria should also include the protection of the most vulnerable groups of the population.

These criteria, as well as the information concerning the decision-making bodies at national or regional level, should be made publicly available.

Deadlines: Parliament proposes extending a number of the deadlines in the Commission’s proposal. Member States shall ensure that a decision on the price which may be charged for a medicinal product concerned is adopted and communicated to the applicant within 90 days of the receipt of an application submitted. With respect to generic medicinal products, that time limit shall be 30 days, provided that the reference medicinal product has been approved by the competent authorities. Where appropriate, Member States shall use health technology assessment as part of their decision-making process on the pricing of medicinal products.

In regard to a decision on the inclusion of a medicinal product in the scope of the public health insurance scheme, a decision shall be adopted and communicated to the applicant within 90 days of its receipt . With respect to generic medicinal products, that time limit shall be 30 days , provided that the reference medicinal product has already been included in the public health insurance system.

Irrespective of the organisation of their internal procedures, Member States shall ensure that the overall period of time taken by the inclusion procedure and the price approval procedure does not exceed 180 days . With respect to generic medicinal products, that time limit shall not exceed 60 days , provided that the reference medicinal product has already been included in the public health insurance system.

Mediation and remedies procedures: Parliament amended the Commission’s proposal requiring Member States to ensure that effective and rapid mediation or remedies procedures are available to the applicant in case of unjustified delays or non-compliance with the time limits set in the Directive, and in accordance with their national law .

Transparency of decision-making bodies and prices: Member States shall ensure that the competent authorities controlling the prices of medicinal products or determining the coverage of medicinal products by public health insurance systems make publicly available a regularly updated list of the members of their decision-making bodies, together with their declarations of interest. These authorities shall also publish and communicate to the Commission, at least once a year, a complete list of the medicinal products covered by their public health insurance systems and the prices which have been set during the relevant period. Any decision to exclude a medicinal product or a category of medicinal products from the scope of the public health insurance system shall be made publicly available , together with a summary of the statement of reasons.

Report: Parliament considers that a yearly report collecting Member States’ data and information would be more appropriate than a six-monthly report, as proposed by the Commission, in order to allow an accurate overview and relevant trends analysis on the implementation of time limits.

Documents
2013/02/04
   EP - Debate in Parliament
2013/01/25
   EP - Committee report tabled for plenary, 1st reading/single reading
Details

The Committee on the Environment, Public Health and Food Safety adopted the report by Antonyia PARVANOVA (ALDE, BG) on the proposal for a Directive of the European Parliament and of the Council relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems.

It recommends that the European Parliament’s position at first reading, under the ordinary legislative procedure, should amend the Commission’s proposal as follows:

Legal base: Members consider that because this proposal deals specifically with the free movement of medicinal products and the pricing thereof ( a matter that falls within the competence of Member States in the field of public health) , Article 168 of the TFEU should therefore be added to the legal basis.

Scope: this Directive may not call into question a marketing authorisation relating to a medicinal product granted in accordance with the procedure referred to in Directive 2001/83/EC .

Definitions: Members define a “voluntary contractual agreement” as an agreement concluded between public authorities and the marketing authorisation holder for a medicinal product which is neither mandatory nor required by law, nor the only alternative to being included in the national pricing and reimbursement scheme to ensure that agreements are not used as a loophole to avoid the applicability of the Directive. A “ biosimilar medicinal product ” means a similar biological medicinal product approved in accordance with Directive 2001/83/EC. “ Health technology assessment ” (HTA) means an assessment which as a minimum includes the relative efficacy or the short- and long-term effectiveness of the medicinal product compared to other health technologies or interventions in use for treating the associated condition.

Innovative treatments: competent authorities and marketing authorisation holders increasingly engage in contractual agreements to provide patients with access to innovative treatments by including a medicinal product in the scope of public health insurance systems whilst monitoring elements agreed upfront and for a defined period of time in order, in particular, to address evidentiary uncertainties relating to the effectiveness and/or relative efficacy or the appropriate use of a specific medicinal product.

Criteria underlying decisions regulating prices of medicinal products: the criteria underlying any decision directly or indirectly regulating the prices of medicinal products, as well as any measure determining the extent to which they shall be covered by public health insurance systems, should include the assessment of unmet medical needs, clinical and societal benefits and innovation . Such criteria should also include the protection of the most vulnerable groups of the population.

Members consider that in the framework of pricing and reimbursement decisions, the competent authorities responsible for these decisions should not reassess the essential elements on which the marketing authorisation is based, including the quality, safety, efficacy, bioequivalence or biosimilarity of the medicinal product.

Time-periods: the Committee extended a number of the deadlines in the Commission’s proposal. For example, Member States shall ensure that a decision on the price which may be charged for the medicinal product concerned is adopted and communicated to the applicant within 90 days (60 days in Commission proposal) of the receipt of an application submitted. Members recommended a 60-day time limit to decide on the pricing and reimbursement of generic medicines .

Transparency of decision-making bodies and prices: Member States shall ensure that the competent authorities controlling the prices of medicinal products or determining the coverage of medicinal products by public health insurance systems make publicly available a regularly updated list of the members of their decision-making bodies, together with their declarations of interest. These authorities shall also publish and communicate to the Commission, at least once a year, a complete list of the medicinal products covered by their public health insurance systems and the prices which have been set during the relevant period. Any decision to exclude a medicinal product or a category of medicinal products from the scope of the public health insurance system shall be made publicly available , together with a summary of the statement of reasons.

Report: Members consider that a yearly report collecting Member States’ data and information would be more appropriate than a six-monthly report, as proposed by the Commission, in order to allow an accurate overview and relevant trends analysis on the implementation of time limits.

Documents
2013/01/23
   EP - Specific opinion
Documents
2012/12/18
   EP - Vote in committee, 1st reading/single reading
2012/12/11
   EP - Amendments tabled in committee
Documents
2012/12/06
   CSL - Debate in Council
Documents
2012/12/06
   CSL - Council Meeting
2012/11/09
   EP - Committee opinion
Documents
2012/10/25
   EP - Amendments tabled in committee
Documents
2012/10/22
   EP - Amendments tabled in committee
Documents
2012/09/21
   EP - Committee draft report
Documents
2012/07/12
   ESC - Economic and Social Committee: opinion, report
Documents
2012/06/20
   CZ_SENATE - Contribution
Documents
2012/04/25
   IT_SENATE - Contribution
Documents
2012/04/20
   PT_PARLIAMENT - Contribution
Documents
2012/04/19
   EP - Responsible Committee
2012/03/20
   EP - Committee Opinion
2012/03/13
   EP - Committee referral announced in Parliament, 1st reading/single reading
2012/03/01
   EC - Document attached to the procedure
2012/03/01
   EC - Document attached to the procedure
2012/03/01
   EC - Legislative proposal published
Details

PURPOSE: to improve the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems.

PROPOSED ACT: Directive of the European Parliament and of the Council.

BACKGROUND: Council Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems was adopted so as to remove distortions to intra-Community trade in medicinal products. Directive 89/105/EEC has never been amended since its adoption. Its provisions reflect the pharmaceutical market conditions which prevailed more than twenty years ago. However, these conditions have fundamentally changed, for instance with the emergence of generic medicines providing cheaper versions of existing products or the development of increasingly innovative (yet often expensive) research-based medicinal products. In parallel, the constant rise in public expenditure on pharmaceuticals in the last decades has encouraged Member States to devise more complex and innovative pricing and reimbursement systems over time.

Despite the historically positive impact of Directive 89/105/EEC on the internal market for medicines, there is evidence that it does not fully achieve its objectives in the present context :

(1) A gap has emerged between the provisions of the Directive, which describe the main types of pricing and reimbursement procedures established in the 1980s, and the much wider range of cost-containment measures adopted nowadays by Member States. Despite the extensive interpretation of the Directive by the Court of Justice, the implementation of its provisions in national law and the effective enforcement of its principles, in particular by the Commission, have become particularly challenging. This situation not only results in legal uncertainties but also in a reduced transparency of national pricing and reimbursement measures, which negatively affects the smooth functioning of the internal market to the detriment of European patients and pharmaceutical companies.

(2) The time limits for pricing and reimbursement decisions established by Directive 89/105/EEC are regularly exceeded by Member States. This leads to delays in the marketing of medicinal products, which in turn slows down the availability of valuable treatments for patients.

In order to take into account the evolution of the pharmaceutical market and of national policies to control public expenditure on medicines, substantive changes are necessary to all major provisions of Directive 89/105/EEC. Therefore, in the interest of clarity, Directive 89/105/EEC should be replaced . The fundamental objectives and principles of Directive 89/105/EEC remain fully valid in the present context.

IMPACT ASSESSMENT: the proposal to revise the Directive is based on the combination of options recommended in the framework of the impact assessment, namely:

to ensure timely pricing and reimbursement decisions : options A.3/c (regular reports on pricing and reimbursement approval times), A.4/a (shorter time-limits for pricing and reimbursement decisions concerning generic medicinal products) and A.4/b (prohibition of patent linkage and re-assessment of safety features); to ensure the adequacy and effectiveness of the Directive in the current context : options B.3/b (extensive revision of the Directive to clarify its scope and wording) and B.4 (notification of draft national measures to facilitate enforcement).

The possible extension of the Directive to include medical devices was examined in the impact assessment but discarded due to the specificities of this market.

Furthermore, in spite of the difficulty to conclude on the overall cost-benefit balance of reducing the time limits with respect to originator medicines, a reduction from the current 90/180 days to 60/120 days is proposed in light of the positive impact it would have on the swift availability of innovative medicines to patients and on rewarding pharmaceutical innovation when medicines are approved for reimbursement.

LEGAL BASIS: Article 114 of the Treaty on the Functioning of the European Union (TFEU).

CONTENT: t he overall objective of the proposal is to clarify the procedural obligations incumbent upon Member State and to ensure the effectiveness of the Directive, both in avoiding delays in pricing and reimbursement decisions and in preventing barriers to pharmaceutical trade. This shall be done without affecting national social security policies, except as far as it is necessary to achieve the transparency of national procedures and the effectiveness of the internal market legislation.

The proposal maintains the core principles of the existing Directive but also puts forward a comprehensive adaptation of its legal provisions based on the following key elements:

Clarification of the scope of the Directive : the transparency requirements apply to all pricing and reimbursement measures understood in a broad sense, including “demand side” measures to control or promote the prescription of specific medicines. Nevertheless, measures involving public procurement and voluntary contractual agreements with individual companies are excluded from the scope of the Directive in order to avoid interference with other bodies of law.

Comprehensive coverage of national measures and legal clarity : the provisions of the Directive are reworded in accordance with general principles (rather than on the basis of specific national procedures) and incorporate the case-law of the Court of Justice. Several key provisions are clarified and updated to avoid interpretation controversies. In particular, it is made clear that the time limits for pricing and reimbursement decisions include all procedural steps leading to the decision, including health technology assessments where applicable.

Adaptation of the time limits for pricing and reimbursement decisions : the time limits applicable to generic medicines are reduced to 15/30 days when the reference product has already been priced and included in the health insurance system. The time limits applicable to all other medicinal products are reduced to 60/120 days .

However, in cases where national authorities subject medicinal products to health technology assessment procedures in order to assess the relative efficacy or the short- and long-term effectiveness, as an integral part of their decision-making process, the time-limits shall be 90/180 days .

Non-interference of patent and safety issues with pricing and reimbursement procedures : the proposal clarifies that intellectual property rights should not interfere with pricing and reimbursement procedures, as is already the case for marketing authorisation procedures. In addition, elements already assessed in the framework of the marketing authorisation process (quality, safety and efficacy, including bioequivalence) may not be reassessed in the framework of pricing and reimbursement procedures.

Dialogue and enforcement tools : different instruments are put in place to facilitate dialogue on the implementation of the Directive and to ensure its effective enforcement (consultation on draft measures at national level and pre-notification to the Commission, the creation of a remedies procedure in case of non-compliance with the time-limits related to the inclusion of medicinal products in health insurance systems).

BUDGETARY IMPLICATION : the C ommission's proposal has no impact on the European Union budget beyond what is already foreseen for the years to come in the Multiannual Financial Framework. Total ap propriations under headings 1 to 5 of the multiannual financial framework are estimated at EUR 0.859 million (2014); EUR 1.293 million (2015); EUR 1.143 million (2016-2017); EUR 1.093 (2018 action continued).

Documents

Activities

Votes

A7-0015/2013 - Antonyia Parvanova - Am 61S

2013/02/06 Outcome: -: 359, +: 288, 0: 11
FR AT SE CY DK MT SK PT CZ ES EL NL FI LV BE SI LU EE ?? GB IE LT DE RO HU BG IT PL
Total
72
17
19
3
12
2
12
21
20
46
19
26
10
8
20
6
6
6
2
66
11
9
85
31
12
16
62
39
icon: S&D S&D
170

Netherlands S&D

3

Finland S&D

2

Latvia S&D

1

Slovenia S&D

2

Luxembourg S&D

For (1)

1

Estonia S&D

For (1)

1

Hungary S&D

3
icon: Verts/ALE Verts/ALE
58

Austria Verts/ALE

2

Denmark Verts/ALE

2

Portugal Verts/ALE

For (1)

1

Spain Verts/ALE

2

Greece Verts/ALE

1

Netherlands Verts/ALE

3

Finland Verts/ALE

2

Latvia Verts/ALE

1

Belgium Verts/ALE

Abstain (1)

4

Luxembourg Verts/ALE

For (1)

1

Estonia Verts/ALE

For (1)

1

United Kingdom Verts/ALE

5
icon: GUE/NGL GUE/NGL
30

Sweden GUE/NGL

1

Cyprus GUE/NGL

1

Denmark GUE/NGL

1

Spain GUE/NGL

For (1)

1

Greece GUE/NGL

2

Netherlands GUE/NGL

2

Latvia GUE/NGL

For (1)

1

Ireland GUE/NGL

For (1)

1
icon: NI NI
26

Spain NI

Against (1)

1

Belgium NI

For (1)

1

United Kingdom NI

Abstain (1)

4

Hungary NI

Against (1)

Abstain (1)

2

Bulgaria NI

Against (1)

1
icon: EFD EFD
28

France EFD

1

Denmark EFD

Against (1)

1

Greece EFD

2

Netherlands EFD

Against (1)

1

Finland EFD

Abstain (1)

1

Belgium EFD

Abstain (1)

1
icon: ECR ECR
46

Denmark ECR

Against (1)

1

Netherlands ECR

Against (1)

1

Latvia ECR

Against (1)

1

Belgium ECR

Against (1)

1

Lithuania ECR

Against (1)

1

Hungary ECR

Against (1)

1
icon: ALDE ALDE
75

Denmark ALDE

2

Slovakia ALDE

For (1)

1

Greece ALDE

Against (1)

1

Latvia ALDE

Against (1)

1

Slovenia ALDE

Against (1)

1

Luxembourg ALDE

Against (1)

1
3

Lithuania ALDE

Against (1)

1
icon: PPE PPE
225

Denmark PPE

Against (1)

1

Czechia PPE

2

Finland PPE

Against (1)

1

Slovenia PPE

3

Luxembourg PPE

3

Estonia PPE

Against (1)

1

PPE

2

A7-0015/2013 - Antonyia Parvanova - Am 62S

2013/02/06 Outcome: -: 543, +: 66, 0: 62
CY ?? MT LV LU EE AT SI FI DK IE NL LT PT HU SK SE EL CZ BE BG RO GB FR ES PL DE IT
Total
3
2
2
8
6
6
17
6
10
12
11
26
12
20
12
12
19
19
22
20
15
31
67
69
48
45
89
62
icon: GUE/NGL GUE/NGL
30

Cyprus GUE/NGL

1

Latvia GUE/NGL

For (1)

1

Denmark GUE/NGL

1

Ireland GUE/NGL

For (1)

1

Netherlands GUE/NGL

2

Sweden GUE/NGL

1

Greece GUE/NGL

2

Spain GUE/NGL

For (1)

1
icon: NI NI
26
5

Hungary NI

Against (1)

Abstain (1)

2

Belgium NI

For (1)

1

Bulgaria NI

Against (1)

1

Spain NI

Against (1)

1
icon: Verts/ALE Verts/ALE
57

Latvia Verts/ALE

Abstain (1)

1

Luxembourg Verts/ALE

Abstain (1)

1

Estonia Verts/ALE

Abstain (1)

1

Austria Verts/ALE

2

Finland Verts/ALE

Abstain (2)

2

Denmark Verts/ALE

2

Netherlands Verts/ALE

3

Portugal Verts/ALE

Abstain (1)

1

Greece Verts/ALE

Abstain (1)

1

Belgium Verts/ALE

Against (1)

4

United Kingdom Verts/ALE

5

Spain Verts/ALE

2
icon: EFD EFD
30

Finland EFD

Abstain (1)

1

Denmark EFD

Against (1)

1

Netherlands EFD

Against (1)

1

Lithuania EFD

2

Greece EFD

2

Belgium EFD

Abstain (1)

1

France EFD

1
icon: ECR ECR
49

Latvia ECR

Against (1)

1

Denmark ECR

Against (1)

1

Netherlands ECR

Against (1)

1

Lithuania ECR

Against (1)

1

Hungary ECR

Against (1)

1

Belgium ECR

Against (1)

1
icon: ALDE ALDE
76

Latvia ALDE

Against (1)

1

Luxembourg ALDE

Against (1)

1

Slovenia ALDE

Against (1)

1

Finland ALDE

3

Denmark ALDE

2
3

Lithuania ALDE

2

Slovakia ALDE

Against (1)

1

Greece ALDE

Against (1)

1
icon: S&D S&D
169
2

Malta S&D

2

Latvia S&D

Against (1)

1

Luxembourg S&D

Against (1)

1

Estonia S&D

Against (1)

1

Slovenia S&D

2

Finland S&D

2

Ireland S&D

3

Netherlands S&D

3

Hungary S&D

3
icon: PPE PPE
234

PPE

2

Luxembourg PPE

3

Estonia PPE

Against (1)

1

Slovenia PPE

3

Finland PPE

2

Denmark PPE

Against (1)

1

Czechia PPE

2

A7-0015/2013 - Antonyia Parvanova - Résolution législative

2013/02/06 Outcome: +: 559, 0: 72, -: 54
DE IT PL ES FR GB RO BG BE NL EL CZ LT SK PT HU AT IE FI DK SI LV LU EE SE ?? MT CY
Total
91
62
47
51
72
67
31
17
19
26
19
22
12
12
21
12
17
11
10
13
6
8
6
6
20
2
2
3
icon: PPE PPE
237

Czechia PPE

2

Finland PPE

For (1)

1

Denmark PPE

Abstain (1)

1

Luxembourg PPE

3

Estonia PPE

For (1)

1
2
icon: S&D S&D
175

Netherlands S&D

3

Hungary S&D

3

Finland S&D

2

Slovenia S&D

2

Latvia S&D

1

Luxembourg S&D

For (1)

1

Estonia S&D

For (1)

1
icon: ALDE ALDE
76

Greece ALDE

1
3

Slovenia ALDE

For (1)

1

Latvia ALDE

For (1)

1

Luxembourg ALDE

For (1)

1
icon: ECR ECR
49

Belgium ECR

For (1)

1

Netherlands ECR

For (1)

1

Lithuania ECR

1

Hungary ECR

For (1)

1

Denmark ECR

For (1)

1

Latvia ECR

For (1)

1
icon: EFD EFD
33

France EFD

Against (1)

1

Belgium EFD

For (1)

1

Netherlands EFD

For (1)

1

Greece EFD

2

Lithuania EFD

2

Slovakia EFD

For (1)

1

Finland EFD

For (1)

1

Denmark EFD

1
icon: NI NI
26

Spain NI

1
5

Bulgaria NI

Abstain (1)

1

Belgium NI

Against (1)

1

Hungary NI

For (1)

Abstain (1)

2
5
icon: Verts/ALE Verts/ALE
59

Spain Verts/ALE

2

United Kingdom Verts/ALE

5

Belgium Verts/ALE

4

Netherlands Verts/ALE

3

Greece Verts/ALE

Abstain (1)

1

Portugal Verts/ALE

Abstain (1)

1

Austria Verts/ALE

2

Finland Verts/ALE

Abstain (2)

2

Denmark Verts/ALE

2

Latvia Verts/ALE

Abstain (1)

1

Luxembourg Verts/ALE

Abstain (1)

1

Estonia Verts/ALE

Abstain (1)

1
icon: GUE/NGL GUE/NGL
30

Spain GUE/NGL

Against (1)

1

Netherlands GUE/NGL

2

Greece GUE/NGL

2
4

Ireland GUE/NGL

Against (1)

1

Denmark GUE/NGL

1

Latvia GUE/NGL

Against (1)

1

Sweden GUE/NGL

Against (1)

1

Cyprus GUE/NGL

1
AmendmentsDossier
334 2012/0035(COD)
2012/10/10 IMCO 94 amendments...
source: PE-497.814
2012/10/22 ENVI 91 amendments...
source: PE-497.983
2012/10/25 ENVI 145 amendments...
source: PE-498.042
2012/12/11 ENVI 4 amendments...
source: PE-498.122

History

(these mark the time of scraping, not the official date of the change)

activities
  • date: 2012-03-01T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2012/0084/COM_COM(2012)0084_EN.pdf title: COM(2012)0084 type: Legislative proposal published celexid: CELEX:52012PC0084:EN body: EC commission: DG: url: http://ec.europa.eu/enterprise/ title: Enterprise and Industry Commissioner: TAJANI Antonio type: Legislative proposal published
  • date: 2012-03-13T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Employment and Social Affairs committee: EMPL body: EP shadows: group: EPP name: BUŞOI Cristian-Silviu group: S&D name: BORZAN Biljana responsible: True committee: ENVI date: 2014-10-23T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: ALDE name: FARIA José Inácio body: EP responsible: True committee: ENVI date: 2012-04-19T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: ALDE name: PARVANOVA Antonyia body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2012-03-20T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: ALDE name: BUŞOI Cristian-Silviu body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee_full: Legal Affairs committee: JURI body: EP responsible: None committee: JURI date: 2013-01-09T00:00:00 committee_full: Legal Affairs rapporteur: group: EFD name: SPERONI Francesco Enrico
  • body: CSL meeting_id: 3206 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3206*&MEET_DATE=06/12/2012 type: Debate in Council title: 3206 council: Employment, Social Policy, Health and Consumer Affairs date: 2012-12-06T00:00:00 type: Council Meeting
  • date: 2012-12-18T00:00:00 body: EP type: Vote in committee, 1st reading/single reading committees: body: EP responsible: False committee_full: Employment and Social Affairs committee: EMPL body: EP shadows: group: EPP name: BUŞOI Cristian-Silviu group: S&D name: BORZAN Biljana responsible: True committee: ENVI date: 2014-10-23T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: ALDE name: FARIA José Inácio body: EP responsible: True committee: ENVI date: 2012-04-19T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: ALDE name: PARVANOVA Antonyia body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2012-03-20T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: ALDE name: BUŞOI Cristian-Silviu body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee_full: Legal Affairs committee: JURI body: EP responsible: None committee: JURI date: 2013-01-09T00:00:00 committee_full: Legal Affairs rapporteur: group: EFD name: SPERONI Francesco Enrico
  • body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-15&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0015/2013 type: Committee report tabled for plenary, 1st reading/single reading committees: body: EP responsible: False committee_full: Employment and Social Affairs committee: EMPL body: EP shadows: group: EPP name: BUŞOI Cristian-Silviu group: S&D name: BORZAN Biljana responsible: True committee: ENVI date: 2014-10-23T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: ALDE name: FARIA José Inácio body: EP responsible: True committee: ENVI date: 2012-04-19T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: ALDE name: PARVANOVA Antonyia body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2012-03-20T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: ALDE name: BUŞOI Cristian-Silviu body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee_full: Legal Affairs committee: JURI body: EP responsible: None committee: JURI date: 2013-01-09T00:00:00 committee_full: Legal Affairs rapporteur: group: EFD name: SPERONI Francesco Enrico date: 2013-01-25T00:00:00
  • date: 2013-02-04T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20130204&type=CRE type: Debate in Parliament title: Debate in Parliament body: EP type: Debate in Parliament
  • date: 2013-02-06T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=22513&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2013-39 type: Decision by Parliament, 1st reading/single reading title: T7-0039/2013 body: EP type: Results of vote in Parliament
  • date: 2013-03-18T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2013/0168/COM_COM(2013)0168(COR1)_EN.pdf title: COM(2013)0168 type: Amended legislative proposal for reconsultation published celexid: CELEX:52013PC0168:EN body: EC commission: DG: url: http://ec.europa.eu/enterprise/ title: Enterprise and Industry Commissioner: TAJANI Antonio type: Amended legislative proposal for reconsultation published
  • date: 2013-03-21T00:00:00 body: EP/CSL type: Formal reconsultation of Parliament
  • date: 2015-03-07T00:00:00 body: EC type: Proposal withdrawn by Commission commission: DG: url: http://ec.europa.eu/enterprise/ title: Enterprise and Industry Commissioner: TAJANI Antonio
commission
  • body: EC dg: Internal Market, Industry, Entrepreneurship and SMEs commissioner: TAJANI Antonio
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2012-04-19T00:00:00
rapporteur
name: PARVANOVA Antonyia group: Alliance of Liberals and Democrats for Europe abbr: ALDE
shadows
committees/0
body
EP
responsible
False
committee_full
Employment and Social Affairs
committee
EMPL
committees/1
type
Former Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
committees/1
body
EP
shadows
responsible
True
committee
ENVI
date
2014-10-23T00:00:00
committee_full
Environment, Public Health and Food Safety
rapporteur
group: ALDE name: FARIA José Inácio
committees/2
type
Former Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2014-10-23T00:00:00
rapporteur
name: FARIA José Inácio group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/2
body
EP
responsible
True
committee
ENVI
date
2012-04-19T00:00:00
committee_full
Environment, Public Health and Food Safety
rapporteur
group: ALDE name: PARVANOVA Antonyia
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Employment and Social Affairs
committee
EMPL
opinion
False
committees/3
body
EP
responsible
True
committee_full
Environment, Public Health and Food Safety
committee
ENVI
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
opinion
False
committees/4
body
EP
responsible
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
committees/5
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
date
2012-03-20T00:00:00
rapporteur
name: BUŞOI Cristian-Silviu group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/5
body
EP
responsible
False
committee
IMCO
date
2012-03-20T00:00:00
committee_full
Internal Market and Consumer Protection
rapporteur
group: ALDE name: BUŞOI Cristian-Silviu
committees/6
type
Committee Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
opinion
False
committees/6
body
EP
responsible
False
committee_full
Industry, Research and Energy
committee
ITRE
committees/7
type
Former Committee Opinion
body
EP
associated
False
committee_full
Employment and Social Affairs
committee
EMPL
date
committees/7
body
EP
responsible
False
committee_full
Legal Affairs
committee
JURI
committees/8
type
Former Committee Opinion
body
EP
associated
False
committee_full
Employment and Social Affairs
committee
EMPL
opinion
False
committees/8
body
EP
responsible
None
committee
JURI
date
2013-01-09T00:00:00
committee_full
Legal Affairs
rapporteur
group: EFD name: SPERONI Francesco Enrico
committees/9